Trial Profile

A PHASE 1 STUDY to ASSESS the SAFETY and IMMUNOGENICITY of a BROADLY PROTECTIVE MRNA VACCINE JCXH-221 AGAINST SARS-CoV-2 INFECTION and DISEASES

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JCXH 221 (Primary) ; Elasomeran; Tozinameran
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Immorna

Most Recent Events

13 Sep 2024 A protocol has been amended to change in phase from I/II to Phase I with change in number of drug Arms.
13 Sep 2024 Status changed from recruiting to completed.
16 Mar 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 20 Feb 2023 to 20 Mar 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com